Puffiness and fluid retention in the hands and feet, joint aches, wrist tingling (carpal tunnel), and blood sugar creeping up over weeks — most pronounced with MK-677 and somatropin.
These accumulate rather than strike suddenly — reassess and stop rather than pushing the dose up. Check glucose if you can.
A severe persistent headache with vision changes (possible raised intracranial pressure), or symptoms of very high blood sugar — extreme thirst, confusion, vomiting — warrant urgent care.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
A tetra-substituted GHRH(1-29) analog. The four substitutions resist enzymatic degradation. The DAC (Drug Affinity Complex) variant adds a reactive linker that forms a covalent bond with circulating albumin, extending half-life from minutes to roughly one to two weeks — which converts pulsatile GH release into a sustained elevation, a pharmacologically significant departure from normal physiology.
Early-phase human pharmacokinetic work exists from the original developer, showing sustained GH and IGF-1 elevation. Development was not carried through to approval. There are no adequate controlled trials supporting efficacy for any clinical outcome.
Not FDA-approved. No USP monograph. Placed on the FDA's 503A Category 2 list, then removed in April 2026 after the nomination was withdrawn — but not moved to Category 1. It occupies a regulatory grey zone: neither expressly permitted for compounding nor expressly prohibited. Prohibited in sport (WADA S2).
Sustained rather than pulsatile GH elevation is the central unknown; chronic GH-axis stimulation is associated with insulin resistance, oedema, arthralgia, and theoretical malignancy-promotion concerns. Long-term human safety is uncharacterised.
No human trial has established a therapeutic dose. Early pharmacokinetic studies of the DAC form gave single doses to measure half-life — not to show benefit.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.